{'fraction_non_alphanumeric': 0.018404907975460124, 'fraction_numerical': 0.0, 'mean_word_length': 5.743801652892562, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evoked potentials in clinical trials for multiple sclerosis.

Multiple sclerosis produces disruption of conduction in the central nervous system by a variety of mechanisms, relating, in part, to loss of the myelin sheath. Although often not well correlated with the clinical course of the disease in individual patients, the resulting evoked potential (EP) disturbances can serve as measures of an accumulating disease burden, particularly in longitudinal population studies. Accordingly, EPs can serve as useful instruments for assessing the effectiveness of therapeutic agents which may alter the course of the multiple sclerosis. Furthermore, since EPs measure conduction within the central nervous system, they provide a means of directly assessing symptomatic treatments designed to improve central conduction.